Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 212

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Therapeutic miR-21 Silencing Ameliorates Diabetic Kidney Disease in Mice

Open access
Kölling, Malte, Kaucsar, Tamas, Schauerte, Celina, Hübner, Anika, Dettling, Angela, Park, Joon-Keun, Busch, Martin, Wulff, Xaver, Meier, Matthias, Scherf, Kristian, Bukosza, Nóra, Szénási, Gábor, Godó, Mária, Sharma, Amit, Heuser, Michael, Hamar, Peter, Bang, Claudia, Haller, Hermann, Thum, Thomas, Lorenzen, Johan M. · 2017 · Molecular Therapy

Abstract

Diabetic nephropathy is the main cause of end-stage renal disease. MicroRNAs are powerful regulators of the genome, and global expression profiling revealed miR-21 to be among the most highly regulated microRNAs in kidneys of mice with diabetic nephropathy. In kidney biopsies of diabetic patients, miR-21 correlated with tubulointerstitial injury. In situ PCR analysis showed a specific enrichment of miR-21 in glomerular cells. We identified cell division cycle 25a (Cdc25a) and cyclin-dependent kinase 6 (Cdk6) as novel miR-21 targets in mesangial cells. miR-21-mediated repression of Cdc25a and Cdk6 resulted in impaired cell cycle progression and subsequent mesangial cell hypertrophy. miR-21 increased podocyte motility by regulating phosphatase and tensin homolog (Pten). miR-21 antagonism in vitro and in vivo in streptozotocin-induced diabetic mice decreased mesangial expansion, interstitial fibrosis, macrophage infiltration, podocyte loss, albuminuria, and fibrotic- and inflammatory gene expression. In conclusion, miR-21 antagonism rescued various functional and structural parameters in mice with diabetic nephropathy and, thus, might be a viable option in the treatment of patients with diabetic kidney disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ymthe.2016.08.001

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 212

Metadata

Authors
Kölling, M., Kaucsar, T., Schauerte, C., Hübner, A., Dettling, A., Park, J.-K., Busch, M., Wulff, X., Meier, M., Scherf, K., Bukosza, N., Szénási, G., Godó, M., Sharma, A., Heuser, M., Hamar, P., Bang, C., Haller, H., Thum, T., & Lorenzen, J. M.
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2017-01
Volume
25
Issue
1
Pages
165-180
ISSN
1525-0016 (ISSN-L)
OpenAlex
W2568946527
Cited by
212
References
1
FWCI
15.64
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Therapeutic miR-21 Silencing Ameliorates Diabetic Kidney Disease in Mice. https://app.cochat.ai/papers/10.1016/j.ymthe.2016.08.001
The paper
Kölling, M., Kaucsar, T., Schauerte, C., Hübner, A., Dettling, A., Park, J.-K., Busch, M., Wulff, X., Meier, M., Scherf, K., Bukosza, N., Szénási, G., Godó, M., Sharma, A., Heuser, M., Hamar, P., Bang, C., Haller, H., Thum, T., & Lorenzen, J. M. (2017). Therapeutic miR-21 Silencing Ameliorates Diabetic Kidney Disease in Mice. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2016.08.001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.